Oral statins and increased bone-mineral density in postmenopausal women

Lancet

Volumn 355, Issue 9222, 2000, Pages 2218-2219

  Edwards, C J ^a,b   Hart, D J ^a   Spector, T D ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

STATIN;

ADULT; AGED; BONE DENSITY; BONE MINERAL; CONTROLLED STUDY; FEMALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; OSSIFICATION; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 0034709764     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02408-9     Document Type: Article

References (5)

1. Mundy G., Garrett R., Harris S.et al. Stimulation of bone formation in vitro and in rodents by statins. Science. 286:1999;1946-1949.
2. Lloyd M.E., Hart D.J., Nandra D.et al. Relation between insulin-like growth factor-I concentrations, osteoarthritis, bone density, and fractures in the general population. the Chingford study Ann Rheum Dis. 55:1996;870-874.
3. Bauer D., Mundy G., Jamal S.et al. Statin use, bone mass and fracture: an analysis of two prospective studies. J Bone Miner Res. 14(suppl):1999;S179. (abstr).
4. Alberts A.W., Chen J., Kuron G.et al. Mevinolin. a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent Proc Natl Acad Sci USA. 77:1980;3957-3961.
5. Fisher J.E., Rogers M.J., Halasy J.M.et al. Alendronate mechanism of action. geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro Proc Natl Acad Sci USA. 96:1999;133-138.